Jae Young Joung

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Neeraj Agarwal, Arun Azad, Joan Carles et al. · The Lancet · 2023 · 499 citations

Medicine, Pharmacology, Pharmacotherapy +12

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · NEJM Evidence · 2022 · 394 citations

Medicine, Oncology, Pharmacology +17

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Fred Saad, Noel W. Clarke, Mototsugu Oya et al. · The Lancet Oncology · 2023 · 288 citations · Full text

Medicine, Oncology, Pharmacology +16

Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer

Myong Cheol Lim, Suk‐Joon Chang, Boram Park et al. · JAMA Surgery · 2022 · 214 citations · Full text

Medicine, Oncology, Surgery +17

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Karim Fizazi, Arun Azad, Nobuaki Matsubara et al. · Nature Medicine · 2023 · 127 citations · Full text

Medicine, Oncology, Pharmacology +17